Kumar Srinivasan

Executive Vice President & CBO, Turning Point Therapeutics

About Kumar

Kumar Srinivasan is a highly accomplished business development executive with an impressive record of success in both pharma and biotech settings.  He has a broad cross-functional background in business development, licensing, R&D, new product planning, finance and strategy, and is an effective leader of multidisciplinary teams. Kumar joined AstraZeneca in April 2012 to head up business development for the newly constituted AstraZeneca Neuro group and was promoted to his current role in March 2013 as Head of Scientific Partnering & Alliances. In his most recent external position, Kumar was Chief Business Officer at Probiodrug AG, then a private venture funded German company developing novel treatment for Alzheimer’s and inflammatory diseases. Prior to joining Probiodrug, Kumar was Vice President, Global Business Development at Wyeth Pharmaceuticals, where he headed up business development and licensing activities for pre phase 2 opportunities for several therapeutic areas.

See all Board Members